This week’s roundup includes reads about a crucial shift in the life sciences ecosystem; the interplay between the digital future of life science, the development of next generation therapeutics, and the promise of personalized medicine. We also take a look at news about COVID-19 variants and drug pricing. … READ MORE >
covid-19 vaccine
5 things to know in life sciences: Week of Jan. 18
This week, we look at new officials in the government’s COVID-19 response effort, how changes in technology and bioethics are driving clinical trial diversity, and how robotics continues to change surgery and medical device manufacturing. … READ MORE >
5 things to know this week in life sciences: Week of Jan. 11
News this week included Bluebird Bio’s announcement about splitting into two companies, the promise of quantum computing in drug design, and how mRNA platforms offer promise for diseases beyond COVID-19. … READ MORE >
5 things to know this week in life sciences: Week of Dec. 21
With approval of Moderna’s COVID-19 vaccine last week for emergency use, many of us are looking forward to getting vaccinated. But this is also a good time to reflect on the decades of work that laid the groundwork for this lightning fast vaccine development effort. … READ MORE >
5 things to know this week in life sciences: Week of Dec. 14
With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people around the country to accept the vaccine and roll up their sleeves for a shot. … READ MORE >
5 things to know this week in life sciences: Week of Dec. 7
This is the first installment of a new weekly roundup in which we highlight five things you need to know about in the life sciences industry. Here’s the latest, including COVID-19 vaccine news, a deal between Palantir and the FDA, and more. … READ MORE >
CHART OF THE DAY: Vaccine doses for the global population
With the U.S. Food and Drug Administration set to review Pfizer and BioNTech’s COVID-19 vaccine this week for emergency use authorization and Moderna’s vaccine next week, we have passed the “if” phase of questions around a COVID-19 vaccine and are now in the midst of determining the “when and how” of vaccine distribution. … READ MORE >
Looking ahead: next steps for the economy after Pfizer’s promising vaccine news
Pfizer and German biotech firm BioNTech’s Monday announcement that their COVID-19 vaccine candidate has shown to be more than 90% effective in preliminary results from an ongoing trial is a much needed win in the fight against the pandemic. While significant challenges remain, we are likely now closer to the end of the pandemic than the beginning. … READ MORE >
The search for a safe and effective coronavirus vaccine
Americans are tired of the pandemic and the economic, health and political fallout we have collectively experienced from it. While there may be disagreement about the best way to approach the pandemic, it is generally held that a safe, effective COVID-19 vaccine that can be manufactured and distributed at scale is a critical step toward economic recovery. … READ MORE >